Superpower peptides available for pre-order. Get first access.

Peptide science

What is dermorphin?

Dermorphin is a seven-amino-acid mu-opioid peptide from frog skin. See how potency varies by assay, the one 1985 human trial, and its legal status.

Quick answer

Dermorphin is a seven-amino-acid opioid peptide from Phyllomedusa frog skin, with D-alanine at position two and the sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. It was 39 times more potent than morphine on guinea-pig ileum, but potency depends on the assay. It is not FDA-approved, and its only human trial is one 1985 study of 150 surgical patients, never replicated.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

What dermorphin is and how it works

Dermorphin is a seven-amino-acid opioid peptide from the skin of the South American frog Phyllomedusa sauvagei. Dermorphin activates mu-opioid receptors, the receptors morphine acts on to blunt pain signaling. The sequence reads Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, which puts a D-amino acid rare in vertebrate peptides1 at position two.

Vittorio Erspamer's group characterized dermorphin in the early 1980s6, and the isolation and sequencing paper appeared in 19811.

Dermorphin needs that D-alanine for full opioid activity7, and its first four amino acids are the shortest stretch that stays active. Natural opioid peptides break down quickly in the body, and chemists add D-amino acids to improve metabolic stability8.

Dermorphin is far more potent than morphine7 in the assays where both were tested, though the gap depends on the test. Isolated tissue and whole-animal pain tests return very different multiples, so a single number misleads.

Test systemPotency compared with morphine
Guinea-pig ileum (isolated tissue)About 39 times more potent7
Mouse vas deferens (isolated tissue)About 40 times more potent7
Rat analgesia, injected into the brain ventriclesMorphine was 752 to 2,170 times less potent7, depending on the test

Dermorphins act as selective mu-opioid agonists9 rather than spreading across the other opioid receptor types. That selectivity made them models for analgesic chemistry. Human testing of dermorphin never matched that laboratory interest.

Dermorphin evidence comes mostly from animal studies

Most of what is known about dermorphin comes from animal and laboratory pharmacology. The published human record is a single 1985 trial in 150 surgical patients4, and dermorphin was never reintroduced clinically6 afterwards.

That trial compared dermorphin injected into the spinal fluid with morphine given the same way, and with intramuscular pentazocine. Analgesia lasted about 43 hours, against 34 for morphine4.

In mice, dermorphin showed the highest brain influx rate10 of eight opioid peptides tested. Kambo, the Amazonian preparation made from Phyllomedusa bicolor skin, contains dermorphin alongside other peptides11. Severe adverse events are recorded11 in its non-indigenous use. Matses hunters used the dried secretion12 long before that. None of this record has made dermorphin a regulated medicine.

Dermorphin is not FDA-approved or federally scheduled

As of November 2026, dermorphin is not approved for any human use2 in the United States. The federal schedules of controlled substances3 do not list dermorphin either.

No approval also means no reviewed indication, dosage form, strength, or labeling, and no agency-reviewed human dosing information. Horse racing is where dermorphin is banned by name and routinely tested for.

Horse racing bans dermorphin as a Class 1 drug

Racing bans dermorphin outright, placing the peptide in the Racing Commissioners International's Class 1 drug category5. Dermorphin went undetected in racing until 201113, when intelligence from North American racetracks pointed to its use.

Laboratory screens now cover 17 dermorphin peptides14 in equine urine and plasma, down to a few parts per trillion. In dosed horses, dermorphin stayed detectable in plasma for 12 hours15. Urine stayed positive for 48 to 72 hours15, depending on the route.

Metabolism work in human liver microsomes and a zebrafish model pointed to the N-terminal fragment as the best target16. That fragment is well characterized and commercially available, which makes it the practical analyte. Away from doping laboratories, dermorphin now matters mainly to medicinal chemists.

Dermorphin serves as a template for analgesic design

Dermorphin has no approved medical use, and its main role in current science is as a starting structure. Chemists build from that structure toward opioid painkillers designed to carry fewer harms17. The class brings dependence, addiction, and slowed breathing.

A shortened dermorphin analogue acting on mu-opioid receptors outside the brain eased pain behavior in rats18 with chemotherapy-induced nerve pain. Newer linear and cyclic analogues are still tested in isolated tissue and rodent pain models19. What none of that settles is how dermorphin behaves in people.

Dermorphin's safety in humans is not characterized

Dermorphin's safety in people is not characterized, because no modern human studies have examined it. As a full mu-opioid agonist, dermorphin carries the risks of that drug class, led by slowed, shallow breathing. That effect is the proximal cause of death in opioid overdose20.

Mu-opioid drugs also produce physical dependence and addiction17, and what is known about dermorphin and dependence comes from animal work. Claims about dermorphin vary widely in quality, so where you read them matters.

Where can I learn about peptides?

Dermorphin's record is thin in people and dense in animals, which puts weight on who is reporting it. A team of health journalists and licensed clinicians writes and fact-checks Superpower's peptide library, so every claim carries the study behind it.

Making sense of an unapproved opioid peptide also means understanding how peptides work generally. The science behind peptides explains sequence, stability, and receptor targets, with no protocol attached.

IMPORTANT SAFETY INFORMATION

Dermorphin is not approved by the FDA for any medical use. Research on this compound has been limited primarily to laboratory and animal studies, with little to no human clinical trial data available. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. Dermorphin is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

Dermorphin is a full mu-opioid receptor agonist approximately 30 to 40 times more potent than morphine. Based on its opioid mechanism, the following safety considerations apply to any exposure context: respiratory depression (risk proportional to dose and potency; naloxone is the reversal agent for mu-opioid agonists but no clinical protocol exists for dermorphin reversal); opioid-induced sedation; nausea and vomiting; risk of physical dependence with repeated use; unpredictable dose response from unregulated sources; serious adverse events and fatalities have been reported with traditional Kambo application, which contains dermorphin.

Dermorphin should not be used by anyone outside an IRB-approved clinical research study. No FDA-approved indication, label, or human dosing protocol exists. Populations of particular concern based on the mu-opioid agonist mechanism and the absence of human safety data include: individuals with respiratory compromise or sleep apnea; individuals with a history of opioid use disorder; individuals taking benzodiazepines, alcohol, or other CNS depressants; pregnant or breastfeeding individuals; and athletes subject to anti-doping testing. These are illustrative concerns, not a contraindication checklist — there is no approved indication.

No clinical dosing guidance, monitoring protocol, or pharmaceutical-grade formulation exists for dermorphin in humans. Products labeled as dermorphin available through online vendors are unregulated research chemicals with no safety oversight. Dermorphin is classified as a Class 1 prohibited substance by the Association of Racing Commissioners International. Any non-FDA-approved substance used for performance enhancement in human sport would fall under the WADA S0 (non-approved substances) category on the current WADA Prohibited List.

Long-term human safety data does not exist. The totality of the prospective human evidence base consists of one unreplicated 1985 trial involving 50 intrathecal administrations in a postoperative setting.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to dermorphin. Dermorphin is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science